<!DOCTYPE html>
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>fedlex-data-admin-ch-eli-oc-2023-13-fr-docx</title>
</head>
<body><div id="lawcontent">
<div id="preface">
<h1 class="erlasstitel botschafttitel ">Ordonnance<br>sur les certificats attestant la vaccination <br>contre le COVID-19, la guérison du COVID-19 ou la réalisation d’un test de dépistage du COVID-19</h1>
<h2 class="erlasskurztitel ">(Ordonnance COVID-19 certificats)</h2>
<p>Modification du 9 janvier 2023</p>
</div>
<div id="preamble">
<p>Le Département fédéral de l’intérieur,</p>
<p>vu l’art. 33 de l’ordonnance COVID-19 du 4 juin 2021 certificats<sup><a href="#fn-d6e20" id="fnbck-d6e20">1</a></sup>, </p>
<p>arrête:</p>
<div class="footnotes"><p id="fn-d6e20"><sup><a href="#fnbck-d6e20">1</a></sup>  <a href="https://fedlex.data.admin.ch/eli/cc/2021/325" target="_blank">RS <b>818.102.2</b></a></p></div>
</div>
<main id="maintext"><section id="lvl_I"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#lvl_I">I</a>
</h1>
<div class="collapseable"><p>L’annexe 2 de l’ordonnance COVID-19 du 4 juin 2021 certificats est modifiée conformément au texte ci-joint.</p></div></section><section id="lvl_II"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#lvl_II">II</a>
</h1>
<div class="collapseable">
<p>La présente ordonnance entre en vigueur le 1<sup>er</sup> février 2023.</p>
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				<td>
					
					<p>9 janvier 2023</p>
				</td>
				<td>
					
					<p>Département fédéral de l’intérieur:</p>
					<p>Alain Berset</p>
				</td>
			</tr>
		</table></div>
</div></section></main><div id="annex"><section id="annex_2"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_2">Annexe 2</a>
</h1>
<div class="collapseable">
<p> (art. 13, al. 3, 14, 15 et 33)</p>
<section id="annex_2/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_2/lvl_u1">Dispositions particulières applicables aux certificats de vaccination COVID-19</a>
</h2>
<div class="collapseable">
<p class=" man-font-style-italic ">Ch. 3.2.1</p>
<dl>
<dt>3.2.1 </dt>
<dd>Le ch. 3.2 s’applique aux vaccins suivants:</dd>
</dl>
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class=" man-text-align-left ">
					
					<p>Fabricant</p>
				</th>
				<th class=" man-text-align-left ">
					
					<p>Nom(s) du/des produit(s)</p>
				</th>
			</tr>
			<tr>
				
				<td>
					
					<p>Johnson&amp;Johnson</p>
				</td>
				<td>
					
					<p>COVID-19 Vaccine Janssen </p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p>CanSino</p>
				</td>
				<td>
					
					<p>Convidecia (Ad5.CoV2‑S) </p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p>Sanofi Pasteur</p>
				</td>
				<td>
					
					<p>VidPrevtyn Beta</p>
				</td>
			</tr>
		</table></div>
<p class=" man-font-style-italic ">Ch. 3.3.1</p>
<dl>
<dt>3.3.1 </dt>
<dd>Le ch. 3.3 s’applique aux vaccins suivants:</dd>
</dl>
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class=" man-text-align-left ">
					
					<p>Fabricant</p>
				</th>
				<th class=" man-text-align-left ">
					
					<p>Nom(s) du/des produits </p>
				</th>
			</tr>
			<tr>
				
				<td>
					
					<p>AstraZeneca</p>
				</td>
				<td>
					
					<p>Vaxzevria (ChAdOx1 nCoV-19)</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p>Moderna</p>
				</td>
				<td>
					
					<p>Spikevax (mRNA-1273)</p>
					<p>Spikevax Bivalent Original/Omicron BA.1</p>
					<p>Spikevax Bivalent Original/Omicron BA.4-5</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p>Novavax</p>
				</td>
				<td>
					
					<p>Nuvaxovid (NVX-CoV2373)</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p>Indian Council for Medical Research</p>
				</td>
				<td>
					
					<p>Bharat Biotech Covaxin</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p>Pfizer/BioNTech</p>
				</td>
				<td>
					
					<p>Comirnaty (BNT162b2)</p>
					<p>Comirnaty Bivalent Original/Omicron BA.1</p>
					<p>Comirnaty Original/Omicron BA.4/5</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p>Sinopharm <br>Wuhan/Sinopharm <br>Beijing</p>
				</td>
				<td>
					
					<p>BIBP P-CoV</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p>Sinovac</p>
				</td>
				<td>
					
					<p>CoronaVac</p>
				</td>
			</tr>
			<tr>
				
				<td>
					
					<p>Valneva</p>
				</td>
				<td>
					
					<p>Valneva (VLA 2001)</p>
				</td>
			</tr>
		</table></div>
</div></section>
</div></section></div>
</div></body>
</html>
